Indacaterol provides sustained 24 h bronchodilation on once‐daily dosing in asthma: a 7‐day dose‐ranging study
Abstract
Background: Indacaterol is a novel, once‐daily β2‐agonist in development for the treatment of asthma and chronic obstructive pulmonary disease. Studies were required to determine optimal dose(s) for continuing investigation. Objective: A dose‐ranging study was undertaken to evaluate efficacy and safety of indacaterol. Methods: A total of 436 patients with persistent asthma receiving inhaled corticosteroids were randomized to 7 days treatment with once‐daily indacaterol 50, 100, 200, or 400 μg via multi‐dose dry‐powder inhaler (MDDPI; Certihaler™), indacaterol 400 μg via single‐dose dry‐powder inhaler (SDDPI), or placebo. Serial 24‐h spirometry was performed on days 1 and 7. Vital signs, laboratory evaluations, and adverse events were monitored. Results: All doses of indacaterol increased the mean time‐standardized area under the curve of forced expiratory volume in 1 s (FEV1) from 22 to 24 h postdose (P ≤ 0.001 vs placebo) on days 1 and 7, with clinically relevant treatment‐placebo differences of 240, 260, 350, 300, and 380 ml on day 1 and 230, 220, 320, 250, and 270 ml on day 7 for indacaterol 50, 100, 200, and 400 μg via MDDPI and 400 μg via SDDPI, respectively. All doses increased mean FEV1 (P < 0.05 vs placebo) from 5 min to 24 h postdose on days 1 and 7. All doses were well tolerated. Most adverse events were mild‐to‐moderate in severity: most frequently reported were respiratory, thoracic, and mediastinal disorders. Conclusion: Once‐daily dosing with indacaterol provided sustained 24‐h bronchodilation in patients with moderate‐to‐severe asthma, with a satisfactory overall safety profile. Indacaterol 200 μg appears the optimum dose, offering the best efficacy/safety balance.Keywords
This publication has 24 references indexed in Scilit:
- Safety and tolerability of indacaterol in asthma: A randomized, placebo-controlled 28-day studyRespiratory Medicine, 2007
- Indacaterol, a novel inhaled β2-agonist, provides sustained 24-h bronchodilation in asthmaEuropean Respiratory Journal, 2007
- Budesonide once versus twice‐daily administration: meta‐analysisRespirology, 2004
- Adverse Effects of β-AgonistsAmerican Journal of Respiratory Medicine, 2003
- Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthmaJournal of Allergy and Clinical Immunology, 2000
- Effect of Inhaled Formoterol and Budesonide on Exacerbations of AsthmaNew England Journal of Medicine, 1997
- Comparison of Addition of Salmeterol to Inhaled Steroids With Doubling of the Dose of Inhaled SteroidsAmerican Journal of Respiratory and Critical Care Medicine, 1996
- Lung volumes and forced ventilatory flowsEuropean Respiratory Journal, 1993
- Dose‐response study with high‐dose inhaled salmeterol in healthy subjects.British Journal of Clinical Pharmacology, 1992
- Clinical Comparison of Fenoterol and Albuterol Administered by InhalationChest, 1978